Literature DB >> 33451357

Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study.

Justin S Sanchez1, Bernard J Hanseeuw1, Francisco Lopera2, Reisa A Sperling1,3, Ana Baena2, Yamile Bocanegra2, David Aguillon2, Edmarie Guzmán-Vélez1, Enmanuelle Pardilla-Delgado1, Liliana Ramirez-Gomez1, Clara Vila-Castelar1, Jairo E Martinez1, Joshua T Fox-Fuller1,4, Claudia Ramos2, Martin Ochoa-Escudero5, Sergio Alvarez5, Heidi I L Jacobs1,6, Aaron P Schultz1, Jennifer R Gatchel1, J Alex Becker1, Samantha R Katz1, Danielle V Mayblyum1, Julie C Price1, Eric M Reiman7, Keith A Johnson1,3, Yakeel T Quiroz8,9.   

Abstract

BACKGROUND: Neuroimaging studies of autosomal dominant Alzheimer's disease (ADAD) enable characterization of the trajectories of cerebral amyloid-β (Aβ) and tau accumulation in the decades prior to clinical symptom onset. Longitudinal rates of regional tau accumulation measured with positron emission tomography (PET) and their relationship with other biomarker and cognitive changes remain to be fully characterized in ADAD.
METHODS: Fourteen ADAD mutation carriers (Presenilin-1 E280A) and 15 age-matched non-carriers from the Colombian kindred underwent 2-3 sessions of Aβ (11C-Pittsburgh compound B) and tau (18F-flortaucipir) PET, structural magnetic resonance imaging, and neuropsychological evaluation over a 2-4-year follow-up period. Annualized rates of change for imaging and cognitive variables were compared between carriers and non-carriers, and relationships among baseline measurements and rates of change were assessed within carriers.
RESULTS: Longitudinal measurements were consistent with a sequence of ADAD-related changes beginning with Aβ accumulation (16 years prior to expected symptom onset, EYO), followed by entorhinal cortex (EC) tau (9 EYO), neocortical tau (6 EYO), hippocampal atrophy (6 EYO), and cognitive decline (4 EYO). Rates of tau accumulation among carriers were most rapid in parietal neocortex (~ 9%/year). EC tau PET signal at baseline was a significant predictor of subsequent neocortical tau accumulation and cognitive decline within carriers.
CONCLUSIONS: Our results are consistent with the sequence of biological changes in ADAD implied by cross-sectional studies and highlight the importance of EC tau as an early biomarker and a potential link between Aβ burden and neocortical tau accumulation in ADAD.

Entities:  

Keywords:  Alzheimer’s; Amyloid; Autosomal-Dominant; Imaging; Longitudinal; Tau

Mesh:

Substances:

Year:  2021        PMID: 33451357      PMCID: PMC7811244          DOI: 10.1186/s13195-020-00765-5

Source DB:  PubMed          Journal:  Alzheimers Res Ther            Impact factor:   6.982


  54 in total

1.  Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.

Authors:  Eric McDade; Guoqiao Wang; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; David M Holtzman; Nigel J Cairns; Alison M Goate; Daniel S Marcus; John C Morris; Katrina Paumier; Chengjie Xiong; Ricardo Allegri; Sarah B Berman; William Klunk; James Noble; John Ringman; Bernardino Ghetti; Martin Farlow; Reisa A Sperling; Jasmeer Chhatwal; Stephen Salloway; Neill R Graff-Radford; Peter R Schofield; Colin Masters; Martin N Rossor; Nick C Fox; Johannes Levin; Mathias Jucker; Randall J Bateman
Journal:  Neurology       Date:  2018-09-14       Impact factor: 9.910

2.  Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.

Authors:  Yakeel T Quiroz; Reisa A Sperling; Daniel J Norton; Ana Baena; Joseph F Arboleda-Velasquez; Danielle Cosio; Aaron Schultz; Molly Lapoint; Edmarie Guzman-Velez; John B Miller; Leo A Kim; Kewei Chen; Pierre N Tariot; Francisco Lopera; Eric M Reiman; Keith A Johnson
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

3.  Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes.

Authors:  Irene Sintini; Jonathan Graff-Radford; Matthew L Senjem; Christopher G Schwarz; Mary M Machulda; Peter R Martin; David T Jones; Bradley F Boeve; David S Knopman; Kejal Kantarci; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs; Jennifer L Whitwell
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

4.  Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

Authors:  J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz
Journal:  J Prev Alzheimers Dis       Date:  2019

5.  The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors.

Authors:  T Gómez-Isla; W B Growdon; M J McNamara; D Nochlin; T D Bird; J C Arango; F Lopera; K S Kosik; P L Lantos; N J Cairns; B T Hyman
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

6.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Authors:  Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

7.  Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

Authors:  Elizabeth C Mormino; Rebecca A Betensky; Trey Hedden; Aaron P Schultz; Rebecca E Amariglio; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

8.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

Authors:  Randall J Bateman; Chengjie Xiong; Tammie L S Benzinger; Anne M Fagan; Alison Goate; Nick C Fox; Daniel S Marcus; Nigel J Cairns; Xianyun Xie; Tyler M Blazey; David M Holtzman; Anna Santacruz; Virginia Buckles; Angela Oliver; Krista Moulder; Paul S Aisen; Bernardino Ghetti; William E Klunk; Eric McDade; Ralph N Martins; Colin L Masters; Richard Mayeux; John M Ringman; Martin N Rossor; Peter R Schofield; Reisa A Sperling; Stephen Salloway; John C Morris
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.

Authors:  Edmarie Guzmán-Vélez; Jairo Martínez; Kate Papp; Ana Baena; Clara Vila-Castelar; Arabiye Artola; Aaron P Schultz; Yamile Bocanegra; Justin Sanchez; Dorene Rentz; Pierre N Tariot; Eric M Reiman; Reisa Sperling; Keith A Johnson; Francisco Lopera; Yakeel T Quiroz
Journal:  Neurology       Date:  2020-07-01       Impact factor: 9.910

10.  A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia.

Authors:  Michael J Pontecorvo; Michael D Devous; Ian Kennedy; Michael Navitsky; Ming Lu; Nicholas Galante; Stephen Salloway; P Murali Doraiswamy; Sudeepti Southekal; Anupa K Arora; Anne McGeehan; Nathaniel C Lim; Hui Xiong; Stephen P Truocchio; Abhinay D Joshi; Sergey Shcherbinin; Brian Teske; Adam S Fleisher; Mark A Mintun
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

View more
  13 in total

Review 1.  The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.

Authors:  Giovanni B Frisoni; Daniele Altomare; Dietmar Rudolf Thal; Federica Ribaldi; Rik van der Kant; Rik Ossenkoppele; Kaj Blennow; Jeffrey Cummings; Cornelia van Duijn; Peter M Nilsson; Pierre-Yves Dietrich; Philip Scheltens; Bruno Dubois
Journal:  Nat Rev Neurosci       Date:  2021-11-23       Impact factor: 34.870

2.  CSF phosphorylated tau as an indicator of subsequent tau accumulation.

Authors:  Petrice M Cogswell; Heather J Wiste; Michelle M Mielke; Christopher G Schwarz; Stephen D Weigand; Val J Lowe; Terry M Therneau; David S Knopman; Jonathan Graff-Radford; Prashanthi Vemuri; Matthew L Senjem; Jeffrey L Gunter; Alicia Algeciras-Schimnich; Ronald C Petersen; Clifford R Jack
Journal:  Neurobiol Aging       Date:  2022-05-26       Impact factor: 5.133

3.  Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease.

Authors:  Heidi I L Jacobs; John Alex Becker; Kenneth Kwong; Diana Munera; Liliana Ramirez-Gomez; Nina Engels-Domínguez; Justin S Sanchez; Clara Vila-Castelar; Ana Baena; Reisa A Sperling; Keith A Johnson; Francisco Lopera; Yakeel T Quiroz
Journal:  Alzheimers Dement       Date:  2022-03-17       Impact factor: 16.655

4.  Regional Aβ-tau interactions promote onset and acceleration of Alzheimer's disease tau spreading.

Authors:  Wha Jin Lee; Jesse A Brown; Hye Ryun Kim; Renaud La Joie; Hanna Cho; Chul Hyoung Lyoo; Gil D Rabinovici; Joon-Kyung Seong; William W Seeley
Journal:  Neuron       Date:  2022-04-19       Impact factor: 18.688

5.  Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial.

Authors:  Clara Vila-Castelar; Pierre N Tariot; Kaycee M Sink; David Clayton; Jessica B Langbaum; Ronald G Thomas; Yinghua Chen; Yi Su; Kewei Chen; Nan Hu; Margarita Giraldo-Chica; Carlos Tobón; Natalia Acosta-Baena; Ernesto Luna; Marisol Londoño; Paula Ospina; Victoria Tirado; Claudia Muñoz; Eliana Henao; Yamile Bocanegra; Sergio Alvarez; Silvia Rios-Romenets; Valentina Ghisays; Dhruman Goradia; Wendy Lee; Ji Luo; Michael H Malek-Ahmadi; Hillary D Protas; Francisco Lopera; Eric M Reiman; Yakeel T Quiroz
Journal:  Alzheimers Dement       Date:  2022-02-01       Impact factor: 16.655

6.  Cortical thickness across the lifespan in a Colombian cohort with autosomal-dominant Alzheimer's disease: A cross-sectional study.

Authors:  Joshua T Fox-Fuller; Heirangi Torrico-Teave; Federico d'Oleire Uquillas; Kewei Chen; Yi Su; Yinghua Chen; Michael Brickhouse; Justin S Sanchez; Cinthya Aguero; Heidi I L Jacobs; Olivia Hampton; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Daniel C Aguirre-Acevedo; Ana Baena; Arabiye Artola; Jairo Martinez; Celina F Pluim; Sergio Alvarez; Martin Ochoa-Escudero; Eric M Reiman; Reisa A Sperling; Francisco Lopera; Keith A Johnson; Bradford C Dickerson; Yakeel T Quiroz
Journal:  Alzheimers Dement (Amst)       Date:  2021-09-14

Review 7.  Neurodegeneration and convergent factors contributing to the deterioration of the cytoskeleton in Alzheimer's disease, cerebral ischemia and multiple sclerosis (Review).

Authors:  Johanna Andrea Gutiérrez-Vargas; John Fredy Castro-Álvarez; Jose Fernando Zapata-Berruecos; Komal Abdul-Rahim; Anibal Arteaga-Noriega
Journal:  Biomed Rep       Date:  2022-02-18

Review 8.  Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer's Disease and Other Tauopathies.

Authors:  Cinzia Maschio; Ruiqing Ni
Journal:  Front Aging Neurosci       Date:  2022-04-22       Impact factor: 5.702

9.  Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease.

Authors:  Edmarie Guzmán-Vélez; Ibai Diez; Dorothee Schoemaker; Enmanuelle Pardilla-Delgado; Clara Vila-Castelar; Joshua T Fox-Fuller; Ana Baena; Reisa A Sperling; Keith A Johnson; Francisco Lopera; Jorge Sepulcre; Yakeel T Quiroz
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-05       Impact factor: 12.779

10.  (-)-Epigallocatechin-3-Gallate Diminishes Intra-and Extracellular Amyloid-Induced Cytotoxic Effects on Cholinergic-like Neurons from Familial Alzheimer's Disease PSEN1 E280A.

Authors:  Viviana Soto-Mercado; Miguel Mendivil-Perez; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio
Journal:  Biomolecules       Date:  2021-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.